©The Author(s) 2016.
World J Clin Oncol. Oct 10, 2016; 7(5): 387-394
Published online Oct 10, 2016. doi: 10.5306/wjco.v7.i5.387
Published online Oct 10, 2016. doi: 10.5306/wjco.v7.i5.387
Table 1 Clinical and pathological general features
| Features | n = 98 (%) |
| Median age | 49 ± 9 |
| Clinical stage | |
| II | 13 (13.3) |
| III | 85 (86.73) |
| Histologic grade | |
| II | 23 (23.5) |
| III | 74 (75.5) |
| Subtype histologic | |
| Ductal | 95 (96.9) |
| Lobular | 2 (2.1) |
| Neoadjuvant chemotherapy | |
| AC | 9 (9.2) |
| AC-Taxane | 86 (87.7) |
| Taxane alone | 3 (3.1) |
| Surgery | |
| Tumorectomy | 29 (29.6) |
| Mastectomy | 65 (66.3) |
| Unknown | 4 (4.1) |
| Inflammatory | |
| No | 69 (70.4) |
| Yes | 29 (29.6) |
| pCR | |
| No | 69 (70.4) |
| Yes | 29 (29.6) |
| Recurrence | |
| No | 56 (57.1) |
| Yes | 42 (42.9) |
| Death | |
| No | 53 (54.1) |
| Yes | 45 (45.9) |
- Citation: Castaneda CA, Mittendorf E, Casavilca S, Wu Y, Castillo M, Arboleda P, Nunez T, Guerra H, Barrionuevo C, Dolores-Cerna K, Belmar-Lopez C, Abugattas J, Calderon G, De La Cruz M, Cotrina M, Dunstan J, Gomez HL, Vidaurre T. Tumor infiltrating lymphocytes in triple negative breast cancer receiving neoadjuvant chemotherapy. World J Clin Oncol 2016; 7(5): 387-394
- URL: https://www.wjgnet.com/2218-4333/full/v7/i5/387.htm
- DOI: https://dx.doi.org/10.5306/wjco.v7.i5.387